P621: REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT
Mazyar Shadman,
Bhavini Srivastava,
Sima Patel,
Chadi Saifan,
Monika Salkar,
Bruno Emond,
Priyanka Gogna,
Ameur Manceur,
Marie-Helene Lafeuille,
Deborah Stephens
Affiliations
Mazyar Shadman
1 Fred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle, WA, United States
Bhavini Srivastava
2 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, United States
Sima Patel
2 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, United States
Chadi Saifan
2 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, United States
Monika Salkar
2 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, United States
Bruno Emond
3 Analysis Group, Inc., Montréal, QC, Canada
Priyanka Gogna
3 Analysis Group, Inc., Montréal, QC, Canada
Ameur Manceur
3 Analysis Group, Inc., Montréal, QC, Canada
Marie-Helene Lafeuille
3 Analysis Group, Inc., Montréal, QC, Canada
Deborah Stephens
4 Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States
